JNJ

224.58

-1.27%↓

UNH

368.46

-0.15%↓

TMO

465.03

-0.91%↓

ISRG

450.36

-1.58%↓

ABT

87.91

-1.79%↓

JNJ

224.58

-1.27%↓

UNH

368.46

-0.15%↓

TMO

465.03

-0.91%↓

ISRG

450.36

-1.58%↓

ABT

87.91

-1.79%↓

JNJ

224.58

-1.27%↓

UNH

368.46

-0.15%↓

TMO

465.03

-0.91%↓

ISRG

450.36

-1.58%↓

ABT

87.91

-1.79%↓

JNJ

224.58

-1.27%↓

UNH

368.46

-0.15%↓

TMO

465.03

-0.91%↓

ISRG

450.36

-1.58%↓

ABT

87.91

-1.79%↓

JNJ

224.58

-1.27%↓

UNH

368.46

-0.15%↓

TMO

465.03

-0.91%↓

ISRG

450.36

-1.58%↓

ABT

87.91

-1.79%↓

Search

Guardant Health Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

91.87 4.83

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

87.21

Max

92.15

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-36M

-128M

Pardavimai

16M

281M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-45.684

Darbuotojai

2,490

EBITDA

-37M

-119M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+47.07% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2B

12B

Ankstesnė atidarymo kaina

87.04

Ankstesnė uždarymo kaina

91.87

Naujienos nuotaikos

By Acuity

50%

50%

155 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-03 23:47; UTC

Uždarbis

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

2026-05-03 22:35; UTC

Uždarbis

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

2026-05-03 23:39; UTC

Rinkos pokalbiai

Gold Edge Higher Amid Signs of Resilience -- Market Talk

2026-05-03 23:34; UTC

Rinkos pokalbiai

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

2026-05-03 23:32; UTC

Uždarbis

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

2026-05-03 23:30; UTC

Rinkos pokalbiai

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

2026-05-03 23:20; UTC

Rinkos pokalbiai

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

2026-05-03 23:16; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

2026-05-03 22:57; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

2026-05-03 22:57; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

2026-05-03 22:57; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

2026-05-03 22:57; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

2026-05-03 22:57; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

2026-05-03 22:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-03 22:45; UTC

Rinkos pokalbiai

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

2026-05-03 22:20; UTC

Uždarbis

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

2026-05-03 22:08; UTC

Uždarbis

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

2026-05-03 22:05; UTC

Uždarbis

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

2026-05-03 22:05; UTC

Uždarbis

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

2026-05-03 22:05; UTC

Uždarbis

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

2026-05-03 22:04; UTC

Uždarbis

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

2026-05-03 22:03; UTC

Uždarbis

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

2026-05-03 22:03; UTC

Uždarbis

NAB 1H Cash Return on Equity 8.5%>NAB.AU

2026-05-03 22:02; UTC

Uždarbis

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

2026-05-03 22:02; UTC

Uždarbis

NAB 1H Cash Earnings A$2.64B>NAB.AU

2026-05-03 22:02; UTC

Uždarbis

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

2026-05-03 22:01; UTC

Uždarbis

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

2026-05-03 22:01; UTC

Uždarbis

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

2026-05-03 22:01; UTC

Uždarbis

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

2026-05-03 15:06; UTC

Uždarbis

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

47.07% į viršų

12 mėnesių prognozė

Vidutinis 128.83 USD  47.07%

Aukščiausias 175 USD

Žemiausias 85 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

17

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

155 / 347 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat